Evidence map›Paper›PMID 36030311›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2022

Levodopa responsiveness in Parkinson's disease: harnessing real-life experience with machine-learning analysis.

Ruth Djaldetti, Ben Hadad, Johnathan Reiner, Bella Askenazi Kharash, Boaz Lerner

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ruth DjaldettiDepartment of Neurology, Movement Disorders Clinic, Rabin Medical Center-Beilinson Hospital, Petach Tikva; Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ben HadadDepartment of Industrial Engineering and Management, Ben-Gurion University of the Negev, 8410501, Beer Sheva, Israel.
Johnathan ReinerDepartment of Neurology, Movement Disorders Clinic, Rabin Medical Center-Beilinson Hospital, Petach Tikva; Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Bella Askenazi KharashDepartment of Neurology, Movement Disorders Clinic, Rabin Medical Center-Beilinson Hospital, Petach Tikva; Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Boaz LernerDepartment of Industrial Engineering and Management, Ben-Gurion University of the Negev, 8410501, Beer Sheva, Israel. boaz@bgu.ac.il.ORCID 0000-0003-0165-3663
Tel Aviv University · ILBen-Gurion University of the Negev · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Responsiveness to levodopa varies greatly among patients with Parkinson's disease (PD). The factors that affect it are ill defined. The aim of the study was to identify factors predictive of long-term response to levodopa. The medical records of 296 patients with PD (mean age of onset, 62.2 ± 9.7 years) were screened for demographics, previous treatments, and clinical phenotypes. All patients were assessed with the Unified PD Rating Scale (UPDRS)-III before and 3 months after levodopa initiation. Regression and machine-learning analyses were used to determine factors that are associated with levodopa responsiveness and might identify patients who will benefit from treatment. The UPDRS-III score improved by ≥ 30% (good response) in 128 patients (43%). On regression analysis, female gender, young age at onset, and early use of dopamine agonists predicted a good response. Time to initiation of levodopa treatment had no effect on responsiveness except in patients older than 72 years, who were less responsive. Machine-learning analysis validated these factors and added several others: symptoms of rigidity and bradykinesia, disease onset in the legs and on the left side, and fewer white vascular ischemic changes, comorbidities, and pre-non-motor symptoms. The main determinants of variations in levodopa responsiveness are gender, age, and clinical phenotype. Early use of dopamine agonists does not hamper levodopa responsiveness. In addition to validating the regression analysis results, machine-learning methods helped to determine the specific clinical phenotype of patients who may benefit from levodopa in terms of comorbidities and pre-motor and non-motor symptoms.

Indexed as

LevodopaParkinson DiseaseAntiparkinson AgentsDopamine AgonistsFemaleHumansMachine LearningAntiparkinson AgentsDopamine AgonistsLevodopaComorbiditiesLevodopa responsivenessMachine learningParkinson's diseasePre-motor symptomsRigidity

Identifiers

PMID36030311
OpenAlexW4293348895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.